Prot #1386.12: A Randomized, Double-Masked, Placebo-Controlled Exploratory Study to Evaluate Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Orally Administered BI 1467335 for 12 Weeks with a 12 Week Follow Up Period in Patients with Nonpro

Project: Research project

Project Details

StatusFinished
Effective start/end date3/25/19 → 3/25/22

Funding

  • Boehringer Ingelheim Pharmaceuticals, Inc. (Prot #1386.12)